Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 19,656	$ 3,564	$ 42,317	$ 9,731
General and administrative	5,588	3,688	15,005	8,086
Total operating expenses	25,244	7,252	57,322	17,817
Loss from operations	(25,244)	(7,252)	(57,322)	(17,817)
Other income (expense):
Interest income	567	5	856	9
Interest expense	(147)	0	(393)	0
Other income	347	0	987	0
Change in fair value of non-marketable equity securities	(202)	(364)	(745)	(645)
Gain on sale of PNAi technology		0	0	2,691
Total other income (expenses)	565	(359)	705	2,055
Net loss	(24,679)	(7,611)	(56,617)	(15,762)
Change in unrealized loss on marketable securities	(127)	0	(279)	0
Total loss and other comprehensive loss	$ (24,806)	$ (7,611)	$ (56,896)	$ (15,762)
Net loss per share attributable to common stockholders, basic	$ (0.91)	$ (0.36)	$ (2.16)	$ (1.46)
Net loss per share attributable to common stockholders, diluted	$ (0.91)	$ (0.36)	$ (2.16)	$ (1.46)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	27,215,874	21,265,519	26,184,816	10,793,436
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	27,215,874	21,265,519	26,184,816	10,793,436